GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today that it has signed a new three-year contract with the Department of Homeland Security (DHS) to support the development and manufacture of novel adenovector-based vaccines against foot and mouth disease (FMD). Under the new agreement, GenVec will receive up to $6 million in program funding the first year and up to $15 million over three years if DHS exercises its annual renewal options under the contract.
